2022. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s63. DOI:https://doi.org/10.25251/skin.6.supp.63.